

In The Name of God The Compassionate, the Merciful



Tehran University of Medical Sciences Children's Medical Center

"Aghia Sophia" Children's Hospital Department of Immunology-Histocompatibility

Memorandum of Understanding between

The Children's Medical Center Hospital and the research centers located in this hospital, including Research Center for Immunodeficiencies, Tehran University of Medical Sciences, Tehran, IRAN

and

The Department of Immunology-Histocompatibility, and Specific Center & Referral Center for Primary Immunodeficiencies – Paediatric Immunology, "Aghia Sophia" Children's Hospital, Athens, GREECE

This memorandum of understanding (MOU) will expand collaboration on scientific programs and research projects, exchanges and training of scientists, sharing of information and technology in support of research activities, sharing of best practices, meetings, workshops and scientific conferences, according to the mutual interests and benefits.

Following is the full text of the MOU

The Children's Medical Center Hospital and the research centers located in this hospital, including Research Center for Immunodeficiencies, Molecular Immunology Research Center, Pediatric Infectious Diseases Research Center, Growth and Development Research Center; Tehran University of Medical Sciences and the Department of Immunology-Histocompatibility, and Specific Center & Referral Center for Primary Immunodeficiencies – Paediatric Immunology, "Aghia Sophia" Children's Hospital, Athens (hereinafter referred to as "the Parties"), realizing the great potential brought forth by the development of science and technology in addressing health and medical issues in two countries; guided by the willingness to strengthen existing cooperation and collaboration between their respective countries in the field of health and medical sciences; considering the strong traditions of research in both parties; with the aim of enhancing and promoting research and development in this field; have agreed upon the followings.

ARTICLE I

- The Parties intend to enhance and expand cooperative efforts in health and medical sciences according to the following general principles:
- *The Parties intend to conduct all activities in the spirit of partnership, mutual cooperation, and scientific excellence

*The cooperation provided for in this MOU does not affect relations currently established between institutions or individuals of IRAN and GREECE rather the Parties intend to identify new areas for joint activities

ARTICLE II

The Parties plan to provide for an expansion of cooperation across a broad range of mutual interests. Initial efforts are to be directed at developing joint activities, addressing common research interests in:

- 1- Primary Immunodeficiencies
- 2- Diagnosis of Immunodeficiencies
- 3- Genetics of Immunodeficiencies
- 4- Treatment of Immunodeficiencies

Other specific areas may be identified from time to time by mutual consent of the Parties.

ARTICLE III

*The methods of cooperation provided for in this MOU include, but are not limited to:

- Coordinating scientific programs and research projects
- Exchanging and training of scientists and delegations
- Sharing of information and technology in support of research activities
- Exchanging information and academics concerning the sharing of best practices;
- Holding meetings, workshops, and scientific conferences.

ARTICLE IV

For each area of cooperation, and initially for those areas identified in Article II, the Parties or their designees intend to identify an appropriate entity to take the lead in overseeing the practical implementation of activities. The appropriate entities of the two Parties shall be responsible for coordinating communications and activities with their counterparts and should be responsible for fulfilling mutually decided responsibilities.

The Parties and appropriate entities intend to consult with each other on a regular basis, reach consensus on proposals of joint research and develop projects under this MOU and evaluate completed projects. The Parties and appropriate entities may hold meetings to discuss issues arising from the implementation of this MOU if necessary. Such meetings will be held in IRAN and GREECE, alternatively.

ARTICLE V

All activities undertaken, pursuant to this MOU, are to be conducted in accordance with the laws and regulations of the IRAN and GREECE and are subject to the availability of personnel, resources, and appropriated funds. The expenses arising from cooperative activities under this MOU will be covered by both Parties.

Projects under this MOU are to be implemented based on consultations between the Parties and project arrangements signed by relevant participants.

ARTICLE VI

The parties and appropriate entities intend to make findings and results publicly known and available by publication in scientific journals. Authorship in these manuscripts will be discussed prior to submission and will be in accordance to the relative individual contributions to the projects. In agreement with the usual guidelines to authorships in scientific publications.

In case of intellectual property generated in the course of the collaboration the ownership to this IP shall be determined by the degree of input in the generation of the inventions. As default the IP will be owned at equal share by the parties.

ARTICLE VII

This MOU should come into force upon signature by the designated representatives of both Parties and shall remain in force for a period of five (5) years. It may be extended for additional five-year periods by the mutual written consent of the Parties. This MOU may be amended by mutual written consent of the Parties.

Name: Nima Rezaei, MD, PhD Chief Executive Director Children's Medical Center Hospital Deputy President of Research Center for Immunodeficiencies

Tehran University of Medical Sciences

Tehran, IRAN

Name: Maria G. Kanariou, MD

Director

Department of Immunology-Histocompatibility Specific Center & Referral Center for Primary Immunodeficiencies - Paediatric Immunology

"Aghia Sophia" Children's Hospital

Athens, GREECE

Sign: Xavapion

Date: 29 June 2012